Search results for "Prognosis."

showing 10 items of 2044 documents

The treatment of advanced gastric cancer: current strategies and future perspectives.

2008

Oncologymedicine.medical_specialtybusiness.industryAdvanced stageCancerHematologyAdvanced gastric cancermedicine.diseasePrognosisGastroenterologyOncologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisbusinessStomach cancerForecastingAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Hereditary ovarian cancer.

2008

Apoptosis is a form of cell death that permits the removal of damaged, senescent or unwanted cells in multicellular organisms, without damage to the cellular microenvironment. Defective apoptosis represents a major causative factor in the development and progression of cancer. The majority of chemotherapeutic agents, as well as radiation, utilize the apoptotic pathway to induce cancer cell death. Resistance to standard chemotherapeutic strategies also seems to be due to alterations in the apoptotic pathway of cancer cells. Recent knowledge on apoptosis has provided the basis for novel targeted therapies that exploit apoptosis to treat cancer. These new target include those acting in the ext…

Oncologymedicine.medical_specialtyendocrine system diseasesColorectal cancerMLH1Germline mutationNeoplastic Syndromes HereditaryInternal medicineGenetic predispositionMedicineHumansGenetic Predisposition to DiseaseGenetic testingOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryBRCA mutationHematologymedicine.diseasePrognosisfemale genital diseases and pregnancy complicationsovarian cancerOncologyMSH2FemalebusinessOvarian cancer
researchProduct

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

2007

To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR).Forty-seven women with non-metastatic, non-inflammatory, large or locally advanced breast cancer were included. Tumour uptake of FDG was evaluated before and after the first course of neoadjuvant chemotherapy. Four indices were used: maximal and average SUV without or with correction by body surface area and glycaemia (SUV(max), SUV(avg), SUV(max-BSA-G) and SUV(avg-BSA-G), respectively). The predictive value of reduction in FDG uptake with respect to pCR was studied by logistic regression analysis. Relationships betwe…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPathological responseAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSensitivity and Specificity030218 nuclear medicine & medical imaging18f fdg pet[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicinemedicineHumansRadiology Nuclear Medicine and imagingNeoadjuvant therapyComputingMilieux_MISCELLANEOUSChemotherapymedicine.diagnostic_testbusiness.industryFdg uptakeReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseasePrognosisNeoadjuvant Therapy3. Good healthClinical trialTreatment OutcomePositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyFemaleRadiopharmaceuticalsbusiness
researchProduct

Expression of clec9a in the oral cancer microenvironment. A preliminary immunohistochemical pilot study

2021

Background The search for treatments to improve cancer survival has led to the emergence of immunotherapy and the study of the tumour microenvironment existing in neoplasms. This preliminary study aims to understand the clinical and pathological relationship of clec9a expression in oral cancer and to explore survival models for future studies. Material and methods: Immunohistochemical study that included 26 patients with a diagnosis of oral squamous cell carcinoma (OSCC) in mobile tongue and floor of the mouth. Clinical and histopathological variables were recorded, and the biomarkers clec9a for dendritic cells and CD8 and CD4 for lymphocytes were used. Results Clec9a was expressed in 58% o…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPilot ProjectsInternal medicineOral Cancer and Potentially malignant disordersmedicineCarcinomaTumor MicroenvironmentHumansLectins C-TypepainGeneral DentistryPathologicalSurvival analysisUNESCO:CIENCIAS MÉDICASMouth neoplasmTumor microenvironmentbusiness.industryResearchquestionnaireCancerpsychometric validationImmunotherapymedicine.diseasePrognosisstomatognathic diseasesOtorhinolaryngologydisabilityHead and Neck NeoplasmsReceptors MitogenCarcinoma Squamous CellImmunohistochemistrySurgeryMouth Neoplasmshead and neck cancerbusiness
researchProduct

Mitotane Concentrations Influence Outcome in Patients With Advanced Adrenocortical Carcinoma

2020

Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding the impact of plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients with advanced ACC treated with mitotane for &ge

OncologymitotaneCancer Researchmedicine.medical_specialtyMultivariate analysisrecurrenceCombination therapyPrognosimedicine.medical_treatment030209 endocrinology & metabolismDiseaselcsh:RC254-282behavioral disciplines and activitiessurvivalArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenocortical carcinomaMitotaneIn patientadrenal cancerObjective responseadrenal cancer; mitotane; prognosis; recurrence; survivalChemotherapybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisprognosisbusinessAdrenal cancer Mitotane Prognosis Recurrence Survivalmedicine.drug
researchProduct

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

2006

Item does not contain fulltext BACKGROUND: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether TP53 mutations classified as functionally inactive (< or=20% of wildtype transactivation ability) had different prognostic and predictive values in CRC compared with mutations that retained significant activity. MATERIALS AND METHODS: TP53 mutations within a large, international database of CRC (n = 3583) were classified ac…

Oncologyp53MaleNutrition and Diseasebinding domainsLymphovascular invasionColorectal cancerDNA Mutational AnalysisAetiology screening and detection [ONCOL 5]Gene mutationmedicine.disease_causeTransactivationVoeding en ZiekteAntineoplastic Combined Chemotherapy ProtocolsDeterminants in Health and Disease [EBP 1]transcriptional activityMutationHematologyExonsMiddle AgedSurvival RateOncologyAdenocarcinomaFemaleColorectal Neoplasmsmedicine.medical_specialtyAdenocarcinomachemotherapy colorectal cancer mutation prognosis TP53 transactivational abilityMolecular epidemiology [NCEBP 1]Breast cancerTranslational research [ONCOL 3]Interventional oncology [UMCN 1.5]Internal medicinemedicineHumansNeoplasm InvasivenessSurvival rateneoplasmsbreast-cancerVLAGAgedNeoplasm StagingHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryInternational Agenciesmedicine.diseaseImmunologyMutationTumor Suppressor Protein p53businessFollow-Up Studies
researchProduct

Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis

2011

Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110ΔE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110ΔE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorou…

Organoplatinum CompoundsColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Blotting WesternFluorescent Antibody TechniqueAntineoplastic AgentsBiologyBioinformaticsReal-Time Polymerase Chain ReactionTransfectionGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineHeat shock proteinCell Line TumormedicineHumansImmunoprecipitationHSP110 Heat-Shock ProteinsneoplasmsCellular localizationComputingMilieux_MISCELLANEOUS030304 developmental biologyDNA Primers0303 health sciencesChemotherapyMicrosatellite instabilityGeneral MedicineTransfectionmedicine.diseasePrognosisdigestive system diseases3. Good healthOxaliplatinOxaliplatin030220 oncology & carcinogenesisCancer cellMutationCancer researchRegression AnalysisMicrosatellite InstabilityFluorouracilColorectal Neoplasmsmedicine.drugPlasmids
researchProduct

Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatect…

2014

Purpose: miRNAs are noncoding RNAs that negatively regulate target mRNA gene expression. Aberrant miRNA expression is associated with prostate cancer pathogenesis. We identified miRNAs as potential biomarkers for prostate cancer diagnosis and prognosis. Materials and Methods: Total RNA was obtained from 10 normal prostate and 50 prostate cancer samples, and analyzed using the GeneChip (R) miRNA 2.0 Array. At a median followup of 92 months (range 2 to 189) an independent cohort of 273 paraffin embedded prostate cancer samples was used for validation by quantitative reverse transcriptase-polymerase chain reaction. Another 92 urine samples from patients undergoing prostate biopsy were evaluate…

PCA3OncologyMalemedicine.medical_specialtyPathologyProstate biopsydiagnosisUrologymedicine.medical_treatmentprostatic neoplasmsProstate cancerProstateInternal medicinemicroRNAmedicineBiomarkers TumorHumansAgedRetrospective StudiesProstatectomymedicine.diagnostic_testbusiness.industryProstatectomyProstatic Neoplasmsmedicine.diseasePrognosismicroRNAsGene Expression Regulation NeoplasticProstate-specific antigenMicroRNAsmedicine.anatomical_structureReal-time polymerase chain reactionEarly Diagnosisprognosisbusinessbiological markersThe Journal of urology
researchProduct

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

2019

International audience; In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leu…

PD-L10301 basic medicinePrognosiSettore MED/06 - Oncologia Medica[SDV]Life Sciences [q-bio]medicine.medical_treatmentImmunologyPredictive significance[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenaBiology03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemNeoplasmsImmune suppressionPD-1Biomarkers TumormedicineAnimalsHumansTumor microenvironmentTumor-infiltrating lymphocytesMelanomaImmunotherapyPrognosismedicine.diseaseImmune checkpoint3. Good healthImmunosurveillance030104 developmental biologyTumor microenvironment030220 oncology & carcinogenesisCancer cellTumor immunologyCancer researchImmunotherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyTumor-infiltrating lymphocytes (TILs)Cellular Immunology
researchProduct

[Atrial fibrillation in patients with COVID-19. Usefulness of the CHA

2021

Resumen Introduccion y objetivos La enfermedad por coronavirus de 2019 (COVID-19) esta causada por el segundo coronavirus del sindrome respiratorio agudo y grave. La fibrilacion auricular (FA) es comun en situaciones agudas, en las que conlleva mas complicaciones y mortalidad. Metodos Analisis del Registro internacional HOPE (NCT04334291); el objetivo es evaluar la informacion pronostica de FA en pacientes con COVID-19. Se realizo un analisis multivariable y un emparejamiento por puntuacion de propension para evaluar la relacion entre FA y mortalidad. Ademas, se evaluo en estos pacientes el impacto en la mortalidad y los eventos embolicos de la puntuacion CHA2DS2-VASc. Resultados Entre los …

PSM propensity score matchingRegistrymedicine.medical_specialtyAF atrial fibrillationArtículo Original030204 cardiovascular system & hematologyRisk AssessmentFibrilación auricular03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsHemorragiaInternal medicineHumansMedicineRegistriesMortalityStrokeEPP emparejamiento por puntuación de propensiónSARS-CoV-2business.industryIncidence (epidemiology)Mortality rateBleedingHazard ratioPronósticoCOVID-19Atrial fibrillationGeneral MedicinePrognosismedicine.diseaseAtrial fibrillationStrokeFA fibrilación auricularCHA2DS2-VAScPredictive value of testsMortalidadPropensity score matchingOriginal ArticleRegistroCardiology and Cardiovascular MedicinebusinessRisk assessmentHumanitiesRevista espanola de cardiologia
researchProduct